L-778,123 (Synonyms:4-[[5-[[4-(3-氯苯基)-3-氧代-1-哌嗪]甲基]-1H-咪唑-1-基]甲基]苯甲腈)
目录号 : KCM12141 CAS No. : 183499-57-2 纯度 : ≥95%
L-778,123 is a dual inhibitor of farnesyl transferase (FTase; IC = 2 nM) and geranylgeranyl transferase type I (GGTase I; IC = 98 nM). It inhibits prenylation of the FTase and GGTase I substrates HDJ2 and Rap1a in PSN-1 pancreatic tumor cells (ECs = 92 and 6,760 nM, respectively). L-778,123 (1-300 μM) also inhibits prenylation of the oncogenic protein Ki-Ras in PSN-1 cells in a concentration-dependent manner. Ex vivo, L-778,123 (35-50 mg/kg per day) reduces HDJ2 and Rap1a prenylation in dog peripheral blood mononuclear cells (PBMCs) but has no effect on Ki-Ras prenylation in patient-derived PBMCs. L-778,123 inhibits lectin-induced expression of the T cell activation markers CD71 and CD25 on human PMBCs (ICs = 6.48 and 84.1 μM, respectively) and inhibits IL-2-induced proliferation of CTLL2 cells (IC = 0.81 μM).
规格 价格 是否有货 数量
5mg
In-stock
10mg
In-stock
25mg
In-stock
50mg
In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

L-778,123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively.

体外研究

L-778,123 showed no significant cytotoxicity (IC50:>100 μM) against HT-29 and A549 cell lines when used alone, but exhibited a synergistic effect with Doxorubicin, with IC50 values reduced to 1.72 and 1.52 μM, respectively.
L-778,123 inhibits the proliferation of myeloid leukemia cell lines, with IC50 values ranging from 0.2 μM to 1.8 μM, and IC50 values in primary samples ranging from 0.1 μM to 61.8 μM.
L-778,123 (0-1 μM, 12 hours; Or 5 μM, 6 hours) inhibits H-RAS isoprenoidization in HL-60 cells and suppresses phosphorylation of MEK-1/2 levels (5 μM, 24 hours).
L-778,123 (0-100 μM, 72 hours) inhibits lymphocyte activation (markers: CD71 or CD25) and function in human PBMCs.

体内研究

L-778,123 (50 mg/kg/day, infusion, 7 days) inhibits HDJ2 and Rap1A isopentenylation in dog PBMC cells, but does not inhibit Ki Ras isopentenylation.

分子式
C22H20ClN5O
分子量
405.88
CAS号
183499-57-2
中文名称
4-[[5-[[4-(3-氯苯基)-3-氧代-1-哌嗪]甲基]-1H-咪唑-1-基]甲基]苯甲腈
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶解性数据
In Vitro:

1 M HCl : ≥ 100 mg/mL (246.38 mM)

DMSO : 20 mg/mL (49.28 mM; ultrasonic and adjust pH to 2 with 1 M HCl)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4638 mL 12.3189 mL 24.6378 mL
5 mM 0.4928 mL 2.4638 mL 4.9276 mL
10 mM 0.2464 mL 1.2319 mL 2.4638 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO → 90% corn oil

    Solubility: ≥ 2.22 mg/mL (5.47 mM); Clear solution

    此方案可获得 ≥ 2.22 mg/mL (5.47 mM,饱和度未知) 的澄清溶液,此⽅案不适⽤于实验周期在半个⽉以上的实验。

    以 1 mL 工作液为例,取 100 μL 22.2 mg/mL 的澄清 DMSO 储备液加到 900 μL ⽟⽶油中,混合均匀。

  • 2.

    请依序添加每种溶剂: 10% DMSO  → 40% PEG300 → 5% Tween-80 → 45% saline

    Solubility: ≥ 2 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (4.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加⼊ 50 μL Tween-80,混合均匀;然后继续加⼊ 450 μL ⽣理盐⽔定容⾄ 1 mL。

  • 3.

    请依序添加每种溶剂: 10% DMSO →  90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (4.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中,混合均匀。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积:

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。